Thu Sep 26 12:55:51 UTC 2024: ## Sarepta Therapeutics Sees Increased Interest from Investors
**September 26th, 2024** – Sarepta Therapeutics, Inc. (NASDAQ:SRPT) saw a boost in investor confidence during the second quarter, with several hedge funds increasing their holdings in the company.
Vanguard Personalized Indexing Management LLC led the charge, boosting its stake in Sarepta by 11.9%, now owning 4,505 shares valued at $712,000. Other notable increases came from Riggs Asset Managment Co. Inc., who increased their holdings by 125% in the first quarter.
This increased investment comes amidst positive analyst sentiment. While Needham & Company LLC reiterated a “buy” rating, UBS Group raised their price objective from $173.00 to $188.00, and Evercore ISI upgraded the stock to an “outperform” rating. Leerink Partners and William Blair also issued positive ratings. Overall, analysts have assigned a “Moderate Buy” rating to SRPT, with a consensus target price of $187.39.
Sarepta Therapeutics recently reported strong second-quarter earnings, exceeding analysts’ expectations for revenue and EPS. The company’s focus on RNA-targeted therapeutics and gene therapies for rare diseases continues to attract attention from investors.
Despite some insider selling activity, Sarepta Therapeutics remains a popular choice for investors seeking exposure to the growing rare disease market. With a strong pipeline and a favorable outlook, the company is poised to continue its upward trajectory.
First Piper 